RET kinase inhibitors

Disclosed herein are compounds of formula I:or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are...

Full description

Saved in:
Bibliographic Details
Main Authors Andrews, Steven W, McKenney, Megan L, Pancaldi, Thomas Pierre Dino, Irvin, Thomas C, McFaddin, Elizabeth A, Condroski, Kevin R, Pilkington-Miksa, Michael Alexander, Kolakowski, Gabrielle R, Anderson, Erin D, Mouret, Tiphaine, Munchhof, Michael J, Kumar, Manoj, Pinto, Marta, Boldron, Christopher Pierre Albert Jean, McLean, Johnathan Alexander
Format Patent
LanguageEnglish
Published 30.04.2024
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Disclosed herein are compounds of formula I:or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.
Bibliography:Application Number: US202218047794